Observational studies and registries that follow patients over time and publish every result.
A long term observational registry, built around a new validated patient reported outcomes measure, following children and young adults aged 4 to 21.
An observational study of children aged 6 to 12 with hypoxic ischemic encephalopathy, comparing outcomes for children receiving emerging cell therapies from their own physicians with children receiving standard care.
Yearly follow up of every participant for at least five years to understand how outcomes last and to detect late safety concerns.
Free plain language guides, webinars, and summaries of our findings, in English and Spanish.
Positive, negative, or inconclusive, all results are published in peer reviewed open access journals.
Every study is approved by an independent ethics committee and registered on ClinicalTrials.gov before any participant enrolls.
An independent Research Review Committee approves our studies. Donors and companies have no role in design, results, or publication.
Results are released to everyone at the same time. No individual, donor, or company receives findings first.
Choose a study to support. Each study has its own funding goal, and every gift designated to a study is used for that study.
Intranasal Insulin for Autism Spectrum Disorder in Children and Young Adults Aged 4 to 21 Years
Funding goal: $TBD
Raised: $0 of $TBD
Real World Outcomes of Intranasal MuSE Exosomes and Stem Cells in Neurological Regenerative Therapy
Funding goal: $TBD
Raised: $0 of $TBD
Integrative Oncology Outcomes Registry Evaluating Naturopathic and Immunotherapy Modalities in Advanced Cancer Patients
Registration in progress
Funding goal: $TBD
Raised: $0 of $TBD
Intra Ovarian MuSE Cell Injection for Perimenopause Symptom Relief and Ovarian Function Restoration
Funding goal: $TBD
Raised: $0 of $TBD
Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders
Funding goal: $TBD
Raised: $0 of $TBD
Intranasal AAV9-PHP.eB Gene Therapy in Cerebral Palsy and Hypoxic Ischemic Encephalopathy
Funding goal: $TBD
Raised: $0 of $TBD
Safety and Outcomes of MUSE Stem Cell Therapy in Individuals With Traumatic Brain Injury
Funding goal: $TBD
Raised: $0 of $TBD
Observational Study of Intranasal IVIG in SARS-CoV-2 Patients Undergoing Medical Tourism
Funding goal: $TBD
Raised: $0 of $TBD
Knowledge of international research environments and regulatory frameworks across diverse regions.
Partnering with clinicians, researchers, and institutions to support ethical observational studies.
Reviewing public regulatory guidance in the US, Europe, and globally.
Collecting and analyzing real world data on outcomes, safety, and patient experiences.
Structured observational research that adds to the broader understanding of emerging therapies.
We support observational research collaborations across North America, Europe, Asia, and Africa to better understand how emerging therapies are studied and experienced in diverse healthcare settings.
Expanded access, also called compassionate use, is a regulatory pathway that licensed physicians may consider for patients with serious or life threatening conditions when no comparable alternatives are available.
We provide general educational information so families can understand when these pathways may be discussed with their own healthcare providers.
Healing Hope International does not facilitate, coordinate, or assist with expanded access or compassionate use.
All requests are initiated and managed exclusively by the patient's licensed physician and the therapy's sponsor.
Healing Hope International is a Texas nonprofit corporation. EIN 43-2287249. Our application for recognition of tax-exempt status under Section 501(c)(3) is pending.
We do not provide medical advice or treatment. All medical decisions should be made with a licensed healthcare provider.
Our Research